Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
Harry R. Büller(Amsterdam University Medical Centers), Jeffrey I. Weitz(McMaster University Medical Centre), Brett P. Monia(Ionis Pharmaceuticals (United States)), Peter Verhamme(KU Leuven), Annelise Segers(Atria), Claudette Bethune(Ionis Pharmaceuticals (United States)), David Gailani(Vanderbilt University Medical Center), Gary E. Raskob(Oklahoma City University), Sanjay Bhanot(Ionis Pharmaceuticals (United States))
Cited by 621
Related Papers
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k